Table 1.
HLA-binding capability of the B cell epitopse derived from HPV16 L1
|
Peptide |
Sequence |
Binding capability (%)* |
|
|---|---|---|---|
| HLA-A2 | HLA-A24 | ||
| 9-mer |
QIFNKPYWL |
66.8 |
40.3 |
| 10-mer |
AQIFNKPYWL |
74.9 |
51.7 |
| Flu M1 |
GILGFVFTL |
116.7 |
ND |
| EBV |
TYGPVFMCL |
ND |
170.6 |
| K-Ras | KLVVVG AGGV | 3.3 | 3.8 |
*HLA-A2 or HLA-A24-binding capability was estimated by increase in mean fluorescence intensity (MFI), determined by flowcytometry after staining of RMA-S/A2 or RMA-S/A24 cells with anti-HLA-A2 or anti-HLA-A24 mAb, as follows; MFI increase (%) = (MFI with a given peptide – MFI without peptide)/(MFI without peptide) X 100. As positive controls, an HLA-A2-binding peptide derived from influenza virus M1 (Flu M1) or an HLA-A24-binding peptide derived from Epstein-Barr virus LMP2 (EBV) was used. As a negative control, a peptide derived from oncogene K-ras was used. ND, not determined.